



## Posters of Distinction

Thursday, 08 September 2022, 13:00 – 13:55 h

### Poster Walk Session 1 Chairs: Amit Assa (Israel), Renz Klomberg (The Netherlands)

P-001	Heather	Armstrong	Canada	<b>Pro-inflammatory and epithelial barrier-modulating effects of specific dietary fibres are dependent on the dietary fibre source and interaction with gut microbiota</b>
P-007	Adi	Eindor	Canada	<b>Paediatric inflammatory bowel disease patients with <i>Clostridioides difficile</i> infection have a disrupted gastrointestinal microbiome and more severe disease outcome</b>
P-009	Konstantinos	Gerasimidis	United Kingdom	<b>Gut metabolomic and compositional signatures predict response to treatment with exclusive enteral nutrition in children with active Crohn's disease</b>
P-010	Konstantinos	Gerasimidis	United Kingdom	<b>The bacterial and fungal microbiome of newly-diagnosed, treatment naïve children with Crohn's disease; the modifying effects of exclusive enteral nutrition and re-introduction of habitual diet</b>
P-012	Edward	Giles	Australia	<b>Specific microbiota drives mucosal responses in inflammatory bowel disease</b>
P-014	Mohammed	Ghiboub	Netherlands	<b>TRYPTOPHAN METABOLITE CHANGES WITH DIET-INDUCED REMISSION IN PAEDIATRIC CROHN'S DISEASE</b>
P-022	Dror	Shouval	Israel	<b>Novel RIPK1 Mutations Causing Infantile-onset IBD with Inflammatory and Fistulizing Features</b>
P-024	Konstantinos	Gerasimidis	United Kingdom	<b>CD-TREAT diet induces remission and improves quality of life in an open label trial in children and adults with active Crohn's disease.</b>
P-028	Jeremy	Adler	United States	<b>Multicentre Evaluation of Patterns of and Reasons for Biologic Discontinuation Among Children with Crohn's Disease</b>
P-069	Renz C W	Klomberg	Netherlands	<b>Early anti-TNF therapy results in higher sustained steroid free remission rates in children with newly-diagnosed Crohn's disease: a prospective observational cohort study</b>

## Posters of Distinction

Thursday, 08 September 2022, 13:00 – 13:55 h

### Poster Walk Session 2 Chairs: Kaija-Leena Kolho (Finland), Chris Burgess (Australia)

<b>P-031</b>	Allison	Bihari	Canada	<b>Letting Go of Control: Experience and Involvement of Parents of Young Adults with Inflammatory Bowel Disease Transitioning from Paediatric to Adult Care</b>
<b>P-036</b>	Jiri	Bronsky	Czech Republic	<b>Post-vaccination immunogenicity of BNT162b2 SARS-CoV-2 vaccine and its predictors in pediatric patients with inflammatory bowel disease</b>
<b>P-038</b>	Seongjin	Choi	Republic of Korea	<b>Epidemiology of Venous Thromboembolism in Paediatric-Onset Inflammatory Bowel Disease: A nationwide population-based study in Korea</b>
<b>P-041</b>	Panagiota	Chondrou	United Kingdom	<b>Rare and severe complications in paediatric inflammatory bowel disease: a case-control study</b>
<b>P-043</b>	Ruben J.	Colman	United States	<b>Model-Informed Precision Dosing with a Pharmacokinetic Dashboard is Now Available at the Bedside for Inflammatory Bowel Disease Patients Receiving Infliximab</b>
<b>P-054</b>	Gili	Focht	Israel	<b><i>The Lémann Index has insufficient validity in children: a report from the prospective multicenter ImageKids study</i></b>
<b>P-065</b>	Panagiota	Chondrou	United Kingdom	<b>An international prospective study of the paediatric IBD incidence: current trends and findings</b>
<b>P-071</b>	Wendy J	Komocsar	United States	<b>A Novel Dual-Company Master Protocol for the Study of IL-23 Inhibitors in Pediatric Crohn's Disease</b>
<b>P-074</b>	Eric	Benchimol	Canada	<b>Predicted Incidence to 2035 of Very Early-Onset Inflammatory Bowel Disease in Two Canadian Provinces: A Population-Based Study</b>
<b>P-075</b>	Sally	Lawrence	Canada	<b>COVID-19 vaccine-induced antibody responses in paediatric inflammatory bowel disease patients treated with anti-TNF therapy.</b>

## Posters of Distinction

Thursday, 08 September 2022, 13:00 – 13:55 h

### Poster Walk Session 3 Chairs: Dror Shouval (Israel), David Wands (United Kingdom)

P-077	Anne	Levine	United States	<b>PROPHYLACTIC ENOXAPARIN FAILS TO PREVENT THROMBOSIS IN HIGH-RISK PEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS</b>
P-078	Dan	Turner	Israel	<b>Predicting pediatric IBD years before diagnosis using routine blood tests</b>
P-081	Rona	Lujan	Israel	<b>Does early initiation of biologics change the natural history of pediatric Crohn's disease? a nationwide study from the epi-IIRN</b>
P-086	Caterina	Strisciuglio	Italy	<b>Disease course of ulcerative proctitis in children: a population based study on behalf of the SIGENP IBD Group.</b>
P-094	Jane	Oba	Brazil	<b>Adolescents and young adults with IBD controlled by the STRIDE-II strategies had poor HRQL in school and work domains rather than physical impairment</b>
P-109	Luca	Scarallo	Italy	<b>Improvement of transmural inflammation with adalimumab versus immunomodulator maintenance therapy in pediatric Crohn's disease: single-center prospective evaluation using PICMI</b>
P-110	Luca	Scarallo	Italy	<b>Early pro-active therapeutic drug monitoring is associated with greater durability of infliximab response: a single center comparative analysis</b>
P-114	Matthew	Smyth	Canada	<b>Symptom self-reporting in Paediatric IBD: the feasibility of use for disease activity monitoring and unique paediatric considerations.</b>
P-121	Dan	Turner	Israel	<b>Pediatric IBD is associated with multiple medical disorders: a systematic evaluation on the nationwide epi-IIRN cohort</b>
P-130	Stephanie	Vuijk	Netherlands	<b>Head-to-Head Pharmacokinetic Analysis of Infliximab Mono- vs Combination Therapy in Paediatric Crohn's Disease</b>
P-132	Anat	Yerushalmy-Feler	Israel	<b>Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Paediatric Crohn's Disease (the SPEED-UP study) - A Multicenter Study from the Paediatric IBD Porto Group of ESPGHAN</b>